Back to Search Start Over

Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.

Authors :
Ledgerwood JE
Zephir K
Hu Z
Wei CJ
Chang L
Enama ME
Hendel CS
Sitar S
Bailer RT
Koup RA
Mascola JR
Nabel GJ
Graham BS
Source :
The Journal of infectious diseases [J Infect Dis] 2013 Aug 01; Vol. 208 (3), pp. 418-22. Date of Electronic Publication: 2013 Apr 30.
Publication Year :
2013

Abstract

Background: H5 DNA priming was previously shown to improve the antibody response to influenza A(H5N1) monovalent inactivated vaccine (MIV) among individuals for whom there was a 24-week interval between prime and boost receipt. This study defines the shortest prime-boost interval associated with an improved response to MIV.<br />Methods: We administered H5 DNA followed by MIV at intervals of 4, 8, 12, 16, or 24 weeks and compared responses to that of 2 doses of MIV (prime-boost interval, 24 weeks).<br />Results: H5 DNA priming with an MIV boost ≥12 weeks later showed an improved response, with a positive hemagglutination inhibition (HAI) titer in 91% of recipients (geometric mean titer [GMT], 141-206), compared with 55%-70% of recipients with an H5 DNA and MIV prime-boost interval of ≤8 weeks (GMT, 51-70) and 44% with an MIV-MIV prime-boost interval of 24 weeks (GMT, 27).<br />Conclusion: H5 DNA priming enhances antibody responses after an MIV boost when the prime-boost interval is 12-24 weeks. Clinical Trials Registration. NCT01086657.

Details

Language :
English
ISSN :
1537-6613
Volume :
208
Issue :
3
Database :
MEDLINE
Journal :
The Journal of infectious diseases
Publication Type :
Academic Journal
Accession number :
23633407
Full Text :
https://doi.org/10.1093/infdis/jit180